Irbesartan IR Granules 50% W/W Pellets

What are Irbesartan IR Granules 50% W/W Pellets?

Irbesartan IR Granules 50% W/W Pellets are a pharmaceutical formulation intermediate containing irbesartan at a stated drug loading of 50% by weight. They are intended for use in further pharmaceutical manufacturing processes. Their precise composition, particle-size distribution, release characteristics, and processing requirements should be confirmed through the approved product specification and technical documentation.

Uses / Applications

Irbesartan is an angiotensin II receptor blocker (ARB) used in finished pharmaceutical medicines for conditions such as:

• Management of hypertension (high blood pressure).

• Treatment of diabetic nephropathy in certain patients with hypertension and type 2 diabetes, as clinically appropriate.

• Formulation development for immediate-release oral pharmaceutical products.

Note: These are general uses of the active ingredient, not confirmation of specific approved indications for this pellet product. The pellets are formulation intermediates and should not be assumed suitable for direct administration.

5. Benefits

Potential formulation-related considerations include:

• Defined drug loading: The stated irbesartan content is 50% w/w.

• Immediate-release designation: Intended for immediate-release formulation development, subject to verification.

• Further processing: May be evaluated for suitable downstream pharmaceutical manufacturing applications.

• Sourcing support: Kelar Pharmachem India supports pharmaceutical sourcing and export requirements.

Actual suitability depends on the product specification, compatibility, and performance testing.

6. Side Effects

Irbesartan-containing finished medicines may be associated with side effects such as:

• Dizziness or light-headedness.

• Fatigue.

• Low blood pressure.

• Increased potassium levels.

• Changes in kidney function.

These are general active-ingredient safety considerations. The pellets themselves are pharmaceutical intermediates and must be assessed according to their intended use and technical documentation.

7. How Does It Work?

Irbesartan blocks the action of angiotensin II at AT1 receptors. This reduces blood-vessel constriction and the effects of aldosterone, helping lower blood pressure. Its effects in a finished medicine depend on the final formulation, dose, product quality, and appropriate clinical use.

8. Dosage Guidelines / Processing Instructions

• The stated drug loading is 50% w/w.

• Confirm the precise composition and release profile against the supplier’s specification.

• Determine the required quantity through formulation calculations and validated manufacturing procedures.

• Evaluate compatibility with excipients and other formulation components.

• Confirm dissolution, stability, and other applicable quality attributes before use.

Important: These pellets are not a patient dosing recommendation. Processing parameters and final-product dosage must be established by qualified pharmaceutical professionals using approved documentation.

9. When Not to Use

Irbesartan-containing finished medicines may be unsuitable in circumstances including:

• Known hypersensitivity to irbesartan or relevant formulation ingredients.

• Pregnancy, particularly when medicines affecting the renin–angiotensin system pose fetal risks.

• Concomitant use with aliskiren in patients with diabetes, where contraindicated.

• Other circumstances identified in the approved product information.

For manufacturing purposes, do not use the intermediate if its identity, quality, suitability, or storage history cannot be verified.

10. Drug / Product Interactions

Potential clinically relevant interactions involving irbesartan include:

• Potassium supplements or potassium-sparing medicines: May increase potassium levels.

• NSAIDs: May affect kidney function and blood-pressure control.

• Lithium: May increase lithium concentrations.

• Other blood-pressure-lowering medicines: May increase the risk of hypotension.

For formulation development, compatibility with excipients and other active ingredients must be established experimentally rather than assumed.

11. Safety Advice

• Handle according to the applicable material safety documentation and site procedures.

• Use appropriate personal protective equipment based on the risk assessment.

• Avoid dust generation and unnecessary exposure during handling.

• Follow validated procedures for sampling, weighing, and processing.

• Verify identity, assay, impurities, and other required quality attributes before use.

12. General Instructions

• Review the current product specification and certificate of analysis, when available.

• Confirm the meaning of “IR” and the stated 50% w/w drug loading with the supplier.

• Establish the suitability of the pellets for the intended dosage-form manufacturing process.

• Follow applicable quality-management and documentation procedures.

• Do not infer regulatory approvals or certifications without supporting evidence.

13. Special Dietary / Lifestyle Tips

Dietary and lifestyle advice applies to patients using a finished irbesartan medicine, not to the pellet intermediate itself. Depending on their clinical circumstances, patients may be advised to monitor blood pressure, follow a balanced diet, and avoid potassium-containing salt substitutes unless approved by their healthcare professional.

14. Comparison with Other Formulations

The comparison is general. Actual performance depends on the validated specifications of each formulation.

15. Precautions & Warnings

• Confirm the exact ingredient, drug loading, and release designation before procurement or processing.

• Do not assume the product’s particle size, excipient composition, coating, or dissolution profile.

• Assess compatibility and stability under the intended manufacturing conditions.

• Ensure all finished medicines meet the applicable quality and regulatory requirements.

• Verify relevant supplier documentation before making claims about manufacturing origin or certifications.

16. Can I Use It With Other Medicines or Ingredients?

The pellets may be considered for combination formulations only after pharmaceutical compatibility and performance have been evaluated. Any proposed combination should be assessed for physical and chemical compatibility, stability, content uniformity, dissolution, and other relevant quality attributes.

Clinical co-administration of medicines containing irbesartan should be evaluated separately by a qualified healthcare professional.

17. Storage

Store according to the manufacturer’s approved product specifications and technical documentation. Refer to the product packaging or applicable technical data sheet for the required storage conditions.

18. Frequently Asked Questions

Q1. What is Irbesartan IR Granules 50% W/W Pellets?

It is a pharmaceutical formulation intermediate containing irbesartan at a stated drug loading of 50% by weight.

Q2. What does 50% w/w mean?

It means that irbesartan represents 50% of the total formulation weight, subject to confirmation in the approved product specification.

Q3. What does IR mean?

IR generally stands for immediate release. The product’s actual release performance should be verified using its technical documentation and relevant testing.

Q4. Are these pellets ready for direct patient use?

They should be treated as a pharmaceutical intermediate for further processing, not as a finished medicine for direct administration.

Q5. Is the packing customizable?

Packing details are available on request and should be confirmed with the supplier.

Q6. Is a technical data sheet available?

The technical data sheet and other supporting documentation can be requested from the supplier.

Q7. What is the proposed trade name?

The proposed trade name is Irbesora IR. It is a suggested name only and is not a claim of trademark registration or regulatory approval.

Q8. What is the production capacity?

Production capacity is available on request and should be confirmed before placing an order.